Kane Akai
Analyst
Chardon
Equibles does not estimate personal net worth.
About Kane Akai
Kane Akai is recorded as Analyst at Chardon. Kane Akai has spoken on 2 investor events across 2 companies, most recently for SAB Biotherapeutics, Inc. on October 20, 2026. Those appearances were for SAB Biotherapeutics, Inc. (SABS) and Metagenomi Therapeutics, Inc. (MGX). The companies whose calls Kane Akai spoke on are classified in the Healthcare sector.
Kane Akai on recent calls
“Okay, well, let's go ahead and get started with this session, Developing Biological Systems as Therapeutics. My name is Kane Akai. I'm the Director of Research.”
“Essentially, we're using a guide RNA to locate a section of DNA where the enzyme then makes a double-stranded break. But that's fairly invasive. The repair process introduces its own set of complications.”
Affiliation history
-
Chardon
Analyst
Transcript header (unverified)
Current